BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In CML, the BCR-ABL fusion gene is often indicative of a poor prognosis, while other mutations lead to varying sensitivity to chemotherapy drugs according to European LeukemiaNet recommendations 2013 [105].